miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 18, 2026

Kevin O'Leary Says No, Interest Rates Won't Ever Go Below 5% Again — But All That It Means Is… 'You're Gonna Buy A House 30% Smaller. That's All'

View original at finance.yahoo.com
Kevin O'Leary Says No, Interest Rates Won't Ever Go Below 5% Again — But All That It Means Is… 'You're Gonna Buy A House 30% Smaller. That's All' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Interest rates will not go below 5% again, or will take a very long time if ever

    60% confidence
  • Using more than one-third of free cash flow after tax to pay mortgage leads to financial problems

    60% confidence
  • For 40 years, 7% was a normal market mortgage rate

    60% confidence
  • Home buyers will adapt to higher rates by buying houses that are 30% smaller

    60% confidence
  • 3.5% to 3.75% mortgage rates were an aberration, not the norm

    60% confidence
  • Interest rates in the U.S. will not be dropped dramatically due to strong economy and rising productivity

    60% confidence
  • People should stop waiting for the Federal Reserve to lower rates and should decide whether the numbers work now

    60% confidence

Data points we hold from this source

Elf Labs · ip assets500 trademarks_and_copyrights
Elf Labs · market expansion30 countries
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Kevin O'Leary Says No, Interest Rates Won't Ever Go Below 5% Again — But All That It Means Is… 'You're Gonna Buy A House 30% Smaller. That's All' — Source | Via News | es.VIA.NEWS